康灃生物科技(上海)股份有限公司(06922)于2026年1月30日发布翌日披露报表。公告显示，公司于当日根据股东于2025年6月20日召开的股东周年大会所授一般授权，以认购方式发行5,595,000股H股，占发行前公司已发行股本约3.9%。本次发行价格为每股港币5.36元。
发行完成后，公司已发行股本由143,438,579股增至149,033,579股，库藏股数量保持不变。公告同时确认有关发行已遵守香港联合交易所有限公司证券上市规则及相关法律法规。
公告由公司董事朱军签署。公司表示，本次发行已获得董事会正式授权，并按适用法规与程序合规进行。交易细节及相关条款可参见公司于2026年1月12日及2026年1月30日刊发的公告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.